Ampersand Biosciences

Ampersand Biosciences is a specialized provider of immunoassay solutions and services, leveraging deep expertise in the Luminex platform to support preclinical research in infectious diseases and immunology. Founded in 2019 (with operations beginning in 2016), the company has carved a niche by developing first-to-market cytokine panels for ferret and hamster models, which are critical for studying influenza, COVID-19, and other respiratory diseases. As a privately owned, grant-funded entity, it operates a hybrid business model combining product sales and contract services, targeting pharmaceutical companies and academic research labs. Its repeated success in securing SBIR grants underscores the innovative and needed nature of its work in filling gaps in preclinical research tools.

Specialized expertise in developing and validating multiplex immunoassays, primarily for the Luminex xMAP platform, with a focus on creating species-specific cytokine panels for underrepresented preclinical animal models (e.g., ferret, hamster).

Ampersand competes in the broad life science research tools market dominated by giants like Bio-Techne (R&D Systems), Thermo Fisher Scientific, and Abcam. Its competitive advantage is deep specialization and first-mover status in providing validated, off-the-shelf cytokine panels for ferret and hamster models, a niche largely ignored by larger players. For custom services, it competes with other specialty CROs and the in-house capabilities of large pharma.